Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: Different patterns in heart transplant recipients and individuals with essential hypertension

Transplantation

Volumn 74, Issue 10, 2002, Pages 1395-1400

  Holm, Torbjørn ^a   Aukrust, Pål ^a   Aagaard, Erik ^b   Ueland, Thor ^a   Haugstad, Tor S ^a   Kjekshus, John ^a   Simonsen, Svein ^a   Frøland, Stig S ^a   Gullestad, Lars ^a   Andreassen, Arne K ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b Ljan Clinic   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ESSENTIAL HYPERTENSION; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; PATHOGENESIS; PRIORITY JOURNAL; RECIPIENT;

EID: 0036851292     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200211270-00009     Document Type: Article

References (35)

1. Starling RC, Cody RJ. Cardiac transplant hypertension. Am J Cardiol 1990; 65: 106.
2. Ventura HO, Malik FS, Mehra MR, et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997; 12: 375.
3. Geny B, Piquard F, Lonsdorfer J, et al. Endothelin and heart transplantation. Cardiovasc Res 1998; 39: 556.
4. Holm T, Aukrust P, Andreassen AK, et al. Peripheral endothelial dysfunction in heart transplant recipients: Possible role of proinflammatory cytokines. Clin Transplant 2000; 14: 218.
5. Berkenboom G, Crasset V, Giot C, et al. Endothelial function of internal mammary artery in patients with coronary artery disease and in cardiac transplant recipients. Am Heart J 1998; 135: 488.
6. Higashi Y, Sasaki S, Kurisu S, et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: Role of endothelium-derived nitric oxide. Circulation 1999; 100: 1194.
7. Node K, Kitakaze M, Yoshikawa H, et al. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997; 30: 405.
8. Moshage H, Kok B, Huizenga JR, et al. Nitrite and nitrate determinations in plasma: A critical evaluation. Clin Chem 1995; 41: 892.
9. Boger RH, Bode-Boger SM. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost 2000; 26: 539.
10. Gullestad L, Simonsen S, Ueland T, et al. Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol 1999; 84: 999.
11. Comini L, Bachetti T, Agnoletti L, et al. Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. Eur Heart J 1999; 20: 1503.
12. Staessen JA, Fagard RH, Lijnen PJ, et al. Mean and range of the ambulatory pressure in normotensive subjects from a meta-analysis of 23 studies. Am J Cardiol 1991; 67: 723.
13. Holm T, Andreassen AK, Aukrust P, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J 2001; 22: 428.
14. Aukrust P, Liabakk N-B, Muller F, et al. Serum levels of tumor necrosis factor (TNF) alpha and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169: 420.
15. Smyth HS, Sleight P, Pickering GW. Reflex regulation of arterial pressure during sleep in man. Circ Res 1969; 24: 109.
16. Reeves RA, Shapiro AP, Thompson ME, et al. Loss of nocturnal decline in blood pressure after cardiac transplantation. Circulation 1986; 73: 401.
17. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997.
18. Rego A, Vargas R, Wroblewska B, et al. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J Pharmacol Exp Ther 1990; 252: 165.
19. Bossaller C, Forstermann U, Hertel R, et al. Cyclosporin A inhibits endothelium-dependent vasodilatation and vascular prostacyclin production. Eur J Pharmacol 1989; 165: 165.
20. Dinh Xuan AT, Fan TP, Higenbottam TW, et al. Cyclosporine in vitro reduces endothelium-dependent relaxation to acetylcholine but does not affect relaxation to nitrovasodilators. Transplant Proc 1990; 22: 1723.
21. Gallego MJ, Garcia Villalon AL, Lopez Farre AJ, et al. Mechanisms of the endothelial toxicity of cyclosporin. A role of nitric oxide, cGMP, and Ca2+. Circ Res 1994; 74: 477.
22. Galatius S, Wroblewski H, Sorensen VB, et al. Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: Different stimuli for release before and after heart transplantation? Am Heart J 1999; 137: 549.
23. Ma XL, Gao F, Liu GL, et al. Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. Pros Natl Acad Sci U S A 1999; 96: 14617.
24. Cosentino F, Luscher TF. Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res 1999; 43: 274.
25. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link? Lancet 1997; 349: 1391.
26. Padgett CM, Whorton AR. Cellular responses to nitric oxide: Role of protein S-thiolation/dethiolation. Arch Biochem Biophys 1998; 358: 232.
27. Yelinova VI, Khramtsov VV, Markel AL. Manifestation of oxidative stress in the pathogenesis of arterial hypertension in ISIAH rats. Biochem Biophys Res Commun 1999; 263: 450.
28. Boger RH, Bode-Boger SM, Sydow K, et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1557.
29. DeFronzo RA, Lee R, Jones A, et al. Effect of insulinopenia and adrenal hormone deficiency on acute potassium clearance. Kidney Int 1980; 17: 586.
30. Wahbi N, Dalton RN, Turner C, et al. Dimethylarginines in chronic renal failure. J Clin Pathol 2001; 54: 470.
31. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652.
32. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989; 13: 261.
33. Durante W, Liao L, Iftikhar I, et al. Differential regulation of L-arginine transport and nitric oxide production by vascular smooth muscle and endothelium. Circ Res 1996; 78: 1075.
34. Stroes ES, Luscher TF, de Groot FG, et al. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 1997; 29: 570.
35. Drexler H. Nitric oxide synthases in the failing human heart: A doubled-edged sword? Circulation 1999; 99: 2972.